Ameriprise
CRNX icon

Ameriprise’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ameriprise’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29M Buy
798,334
+197,144
+33% +$8.81M 0.01% 1171
2025
Q4 		$28M Sell
601,190
-13,626
-2% -$607K 0.01% 1182
2025
Q3 		$25.6M Buy
614,816
+376,206
+158% +$12M 0.01% 1230
2025
Q2 		$6.86M Buy
238,610
+33,556
+16% +$1.04M ﹤0.01% 2101
2025
Q1 		$6.88M Sell
205,054
-150,120
-42% -$5.61M ﹤0.01% 2059
2024
Q4 		$18.2M Buy
355,174
+186,681
+111% +$10.4M ﹤0.01% 1393
2024
Q3 		$8.61M Buy
168,493
+143,695
+579% +$7.41M ﹤0.01% 1927
2024
Q2 		$1.11M Buy
+24,798
New +$1.15M ﹤0.01% 3123

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ameriprise's CRNX Position: Q1 2026 in Review

Ameriprise increased its Crinetics Pharmaceuticals (CRNX) stake by 33% in Q1 2026, buying an estimated $8.81M and bringing the position to 798,334 shares worth $29M. The position accounts for 0.01% of the portfolio, ranked #1171.

Ameriprise first reported a position in CRNX in Q2 2024 and has held it in 8 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Ameriprise held 798,334 shares of Crinetics Pharmaceuticals worth $29M as of Q1 2026.
  • Ameriprise bought 197,144 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $8.81M.
  • Crinetics Pharmaceuticals made up 0.01% of Ameriprise's portfolio in Q1 2026, its #1171 holding.
  • Ameriprise first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.